Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session
Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation over breast conserving surgery
In-booth expert exchange session on breast cancer cryoablation from the perspective of both breast surgeons and interventional oncologists by Sophie Wooldrik, MD & Prof. Tomas Vogl, MD respectively
Three hands-on device trainings, including ProSense®
CAESAREA, Israel, April 22, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the European Conference on Interventional Oncology 2025 (ECIO), which took place on April 13 – 16, 2025 in Rotterdam, the Netherlands. One of the major areas of focus at ECIO 2025 was breast cancer cryoablation, with ProSense® featuring in seven key events at the conference.
IceCure_Medical_Logo
"As minimally invasive technologies like ProSense® have advanced the science of cancer care, interventional oncology is becoming an increasingly viable and preferred pathway for the treatment of breast cancer in Europe, next to current standard of care surgical, medical, and radiological methods," stated Eyal Shamir, IceCure's Chief Executive Officer. "We believe ProSense® is the leading cryoablation system for early-stage breast cancer tumors on the market today, and this was reflected in the number of sessions in which our cryoablation system was featured. We believe that this points to the continued commercial adoption of ProSense® for indications including breast cancer in Europe and other key global markets."
ProSense® was featured in the following.
Two scientific sessions and one poster presentation presenting data from investigator-initiated studies that used ProSense® for breast cancer:
Oral presentation and Q&A by Dr. Sophie M. Wooldrik of the Netherlands, titled: Review of the indications and results of the different techniques of thermal ablation on breast tumors; The treatment of breast cancer with percutaneous thermal ablation – THERMAC; An open label phase 2 screening trial
Conclusion: Only cryoablation met the requirement to proceed to a phase 3 study, with an efficacy rate of 94%, a complication rate of 0%, and a 100% treatment tolerance. 94% of patients were very satisfied or satisfied with the thermal ablation technique, and 95% of patients stated they would choose thermal ablation over breast conserving surgery. 41 women were enrolled in the study, which compared cryoablation to radiofrequency ablation and microwave ablation.
Oral presentation and Q&A by Professor Thomas J. Vogl of Germany, titled: CT-guided cryoablation of primary breast cancer: Evaluation of efficacy and safety
Conclusion: Cryoablation is a safe and effective treatment for primary breast cancer. 45 patients with 56 tumors (mean diameter 1.6 ± 0.7 cm) were treated. The mean overall progression-free survival was 2.9 years (95% with a confidence interval of 2.3-3.6).
Poster presentation titled: Non-surgical treatment of breast cancer: a comparison of outcomes between cryoablation with hormonal therapy versus cryoablation alone and hormonal therapy alone in patients not eligible for surgery
Conclusion: Cryoablation with hormonal therapy reduces tumor size and residual disease more effectively than hormonal therapy or cryoablation alone, making it a promising option for patients not eligible for surgery. 64 patients were not suitable for surgery, and a total of 73 tumors (mean 14.8 mm) were treated. Tumor size reduction was greatest in the cryoablation with hormone therapy (HT) group (94%, mean-reduction of 15.4 mm), followed by cryoablation only (82%, mean reduction of 9.7 mm), and followed by HT only (43%, mean reduction of 4.6 mm).
ProSense® featured during ECIO's Hands-On Device Cryoablation Training Sessions.
The sessions were well attended, and the training was well received.
An in-booth expert exchange session at IceCure's booth was conducted on the perspectives of breast cancer cryoablation from breast surgeons and interventional oncologists by Dr. Wooldrik and Professor Vogl, who had also presented at the scientific sessions.
About ProSense®
The ProSense® Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and China.
Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that minimally invasive technologies such as ProSense have advanced cancer care; the belief that ProSense is the leading cryoablation system for early-stage breast cancer tumors on the market today; and the belief that there will likely be continued commercial adoption of ProSense® for indications, including breast cancer, in Europe and other key global markets. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
